항-DLL3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도

• Main Authors: WANG BAOXIA, SHEN YIJUN, YANG TONG, GUO QINGSONG, WU FANG, MENG LIKAI, GAO BEI, ZHANG WENBO
• Format: Patent
• Language: Korean
• Published: 27.03.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

본 발명은 항-DLL3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도를 개시한다. 본 발명의 항-DLL3 항체는 우수한 내재화 활성을 가지고, 인간 DLL3 단백질과 더 나은 결합 활성을 가지며, 단백질 수준에서 친화력이 모두 비교적 강하다. 본 발명의 DLL3을 표적으로 하는 항체 접합 약물은 우수한 약용성, 생물학적 활성과 체내 및 체외 항종양 활성을 가지며, 이는 SCLC를 포함한 신경내분비 특성을 갖는 종양 환자의 치료에 있어서의 세포독성 약물의 용도를 구현할 수 있다. Disclosed are an anti-DLL3 antibody and a preparation method therefor, a drug conjugate and application thereof. The anti-DLL3 antibody in the present invention has good internalization activity, has better binding activity with human DLL3 protein, and has strong affinity at the protein level. The antibody conjugated drug targeting DLL3 in the present invention has good druggability, biological activity, and anti-tumor activity in vitro and vivo, and can achieve an application of cytotoxic drugs in treating tumor patients comprising SCLC and having neuroendocrine characteristics.